Stock Analysis
Akeso First Half 2024 Earnings: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)
Akeso (HKG:9926) First Half 2024 Results
Key Financial Results
- Revenue: CN¥1.02b (down 72% from 1H 2023).
- Net loss: CN¥238.6m (down by 109% from CN¥2.53b profit in 1H 2023).
- CN¥0.28 loss per share (down from CN¥3.02 profit in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Akeso Earnings Insights
Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Hong Kong.
Performance of the Hong Kong Biotechs industry.
The company's shares are up 13% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Akeso has 1 warning sign we think you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:9926
Akeso
A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.
